Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	40.58	22.35	32.55	45.75	74.59
Short-Term Investments	-	80.4	65.34	-	-
Cash & Short-Term Investments	40.58	102.75	97.89	45.75	74.59
Cash Growth	-60.51%	4.96%	113.99%	-38.67%	660.53%
Prepaid Expenses	2.45	2.07	2.94	2.17	1.32
Total Current Assets	43.03	104.82	100.83	47.92	75.92
Property, Plant & Equipment	21.33	35.28	4.47	5.86	4.47
Other Long-Term Assets	1.99	2.5	4.67	1.09	0.45
Total Assets	66.35	142.6	109.97	54.87	80.83
Accounts Payable	1.18	3.13	2.62	3.13	0.92
Accrued Expenses	2.11	8.14	8.37	3.63	2.83
Current Portion of Leases	4.12	5.43	1.55	1.07	0.99
Current Unearned Revenue	0.4	1.66	1.28	9.79	-
Other Current Liabilities	4.82	1.23	0.66	0.63	0.15
Total Current Liabilities	12.63	19.6	14.47	18.25	4.88
Long-Term Leases	30.26	21.45	0.67	0.38	1.45
Long-Term Unearned Revenue	11.86	12.14	14.08	1.93	-
Total Liabilities	54.75	53.18	29.21	20.55	6.34
Common Stock	0.07	0.06	0.03	0.01	0.01
Additional Paid-In Capital	416.32	400.69	329.39	227.7	224.36
Retained Earnings	-404.79	-311.36	-248.68	-193.4	-149.88
Comprehensive Income & Other	-	0.03	0.01	-	-
Total Common Equity	11.59	89.42	80.75	34.32	74.49
Shareholders' Equity	11.59	89.42	80.75	34.32	74.49
Total Liabilities & Equity	66.35	142.6	109.97	54.87	80.83
Total Debt	34.38	26.88	2.22	1.45	2.44
Net Cash (Debt)	6.2	75.87	95.68	44.29	72.15
Net Cash Growth	-91.83%	-20.70%	116.01%	-38.61%	1013.14%
Net Cash Per Share	4.76	76.17	158.22	170.54	419.98
Filing Date Shares Outstanding	1.32	1.19	0.64	0.26	0.26
Total Common Shares Outstanding	1.31	1.14	0.64	0.26	0.26
Working Capital	30.39	85.22	86.36	29.67	71.03
Book Value Per Share	8.85	78.14	126.86	131.91	288.01
Tangible Book Value	11.59	89.42	80.75	34.32	74.49
Tangible Book Value Per Share	8.85	78.14	126.86	131.91	288.01
Machinery	4.89	3.4	5.35	5.59	3.58
Construction In Progress	-	-	-	-	0.5
Leasehold Improvements	0.49	0.46	0.4	2.11	0.32

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q